Curcumin for radiation dermatitis: A randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients

Radiation Research

Volumn 180, Issue 1, 2013, Pages 34-43

  Ryan, Julie L ^a   Heckler, Charles E ^a   Ling, Marilyn ^a   Katz, Alan ^a   Williams, Jacqueline P ^a   Pentland, Alice P ^a   Morrow, Gary R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CURCUMIN C 3 COMPLEX; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; DESQUAMATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MCGILL PAIN QUESTIONNAIRE; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL;

ADULT; BREAST NEOPLASMS; CURCUMIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; RADIATION DOSAGE; RADIODERMATITIS; RADIOTHERAPY;

EID: 84880532170     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR3255.1     Document Type: Article

References (53)

1. Ryan JL. Ionizing radiation: the good, the bad, and the ugly. J Invest Dermatol 2012; 132(3 Pt 2):985-93.
2. Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, et al. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol 2010; 17(4):94-112.
3. Chen MF, Chen WC, Lai CH, Hung CH, Liu KC, Cheng YH. Predictive factors of radiation-induced skin toxicity in breast cancer patients. BMC Cancer 2010; 10:508.
4. Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006; 54(1):28-46. (Pubitemid 41832455)
5. McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Semin Oncol Nurs 2011; 27(2):e1-17.
6. Bolderston A, Lloyd NS, Wong RK, Holden L, Robb-Blenderman L. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 2006 Aug;14(8):802-17. (Pubitemid 44060993)
7. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595:1-75.
8. Bhagavathula N, Warner RL, DaSilva M, McClintock SD, Barron A, Aslam MN, et al. A combination of curcumin and ginger extract improves abrasion wound healing in corticosteroid-impaired hairless rat skin. Wound Repair Regen 2009; 17(3):360-6.
9. Gopinath D, Ahmed MR, Gomathi K, Chitra K, Sehgal PK, Jayakumar R. Dermal wound healing processes with curcumin incorporated collagen films. Biomaterials 2004; 25(10):1911-7. (Pubitemid 38102266)
10. Jagetia GC, Rajanikant GK. Role of curcumin, a naturally occurring phenolic compound of turmeric in accelerating the repair of excision wound, in mice whole-body exposed to various doses of gamma-radiation. J Surg Res 2004; 120(1):127-38. (Pubitemid 38686539)
11. Phan TA, Halliday GM, Barnetson RS, Damian DL. Melanin differentially protects from the initiation and progression of threshold UV-induced erythema depending on UV waveband. Photodermatol Photoimmunol Photomed 2006; 22(4):174-80. (Pubitemid 44088993)
12. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Current Medicinal Chem 2010; 17(3):190-7.
13. Gao W, Chan JY, Wei WI, Wong TS. Anti-Cancer Effects of Curcumin On Head And Neck Cancers. Anticancer Agents Med Chem 2012 12(9):1110-6.
14. Rajasekaran SA. Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol 2011; 2(1):1-14.
15. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Molecular Cancer 2011; 10:12.
16. Kaefer CM, Milner JA. Herbs and spices in cancer prevention and treatment. In Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton 2011.
17. Shi HS, Gao X, Li D, Zhang QW, Wang YS, Zheng Y, et al. A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation. Int J Nanomedicine 2012; 7:2601-11.
18. Okunieff P, Xu J, Hu D, Liu W, Zhang L, Morrow G, et al. Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines. Int J Radiat Oncol Biol Phys 2006; 65(3):890-8. (Pubitemid 43795823)
19. Cleeland CS, Anderson KO. Assessment of cancer-related symptoms: relevance for CAM research methodology. In: NCI-OCAM, editor. Expert opinions on methodology: Development of cancer CAM symptom research. Bethesda, MD: National Cancer Institute; 2003. p. 67-90.
20. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000; 89(7): 1634-46.
21. Lerman SF, Rudich Z, Shahar G. Distinguishing affective and somatic dimensions of pain and depression: a confirmatory factor analytic study. J Clin Psychol 2010; 66(4):456-65.
22. Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the MD Anderson symptom inventory, head and neck module. Head Neck 2007; 29(10): 923-31.
23. Zinke JL, Lam CS, Harden RN, Fogg L. Examining the cross-cultural validity of the english short-form McGill Pain Questionnaire using the matched moderated regression methodology. Clin J Pain 2010; 26(2):153-62.
24. Lerman SF, Rudich Z, Shahar G. Distinguishing affective and somatic dimensions of pain and depression: a confirmatory factor analytic study. J Clin Psychol 2010; 66(4):456-65.
25. Clarys P, Alewaeters K, Lambrecht R, Barel AO. Skin color measurements: comparison between three instruments: the Chromameter(R), the DermaSpectrometer(R) and the Mexameter(R). Skin Res Technol 2000; 6(4):230-8.
26. Yun IS, Lee WJ, Rah DK, Kim YO, Park BY. Skin color analysis using a spectrophotometer in Asians. Skin Res Technol 2010; 16(3):311-5.
27. Brown KR, Rzucidlo E. Acute and chronic radiation injury. J Vasc Surg 2011; 53(1 Suppl):15S-21S.
28. Burris HA, 3rd, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010; 15(11):1227-37.
29. McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs 2006; 22(3):163-73. (Pubitemid 44163101)
30. Schmuth M, Wimmer MA, Hofer S, Sztankay A, Weinlich G, Linder DM, et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol 2002; 146(6):983-91. (Pubitemid 34779478)
31. Liguori V, Guillemin C, Pesce GF, Mirimanoff RO, Bernier J. Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiother Oncol 1997; 42(2):155-61. (Pubitemid 27132744)
32. Pinnix C, Perkins GH, Strom EA, Tereffe W, Woodward W, Oh JL, et al. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. Int J Radiat Oncol Biol Phys 2012; 83(4):1089-94.
33. Ravo V, Calvanese MG, Di Franco R, Crisci V, Murino P, Manzo R, et al. Prevention of cutaneous damages induced by radiotherapy in breast cancer: an institutional experience. Tumori 2011; 97(6):732-6.
34. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 2005; 23(24):5805-13.
35. Javvadi P, Segan AT, Tuttle SW, Koumenis C. The chemopre-ventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol 2008; 73(5):1491-501. (Pubitemid 351574839)
36. Khafif A, Hurst R, Kyker K, Fliss DM, Gil Z, Medina JE. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg 2005; 132(2):317-21. (Pubitemid 40431151)
37. Khafif A, Lev-Ari S, Vexler A, Barnea I, Starr A, Karaush V, et al. Curcumin: a potential radio-enhancer in head and neck cancer. Laryngoscope 2009; 119(10):2019-26.
38. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269(2):199-225.
39. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal BB, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res 2008; 14(7):2128-36. (Pubitemid 351551125)
40. Hutzen B, Friedman L, Sobo M, Lin L, Cen L, De Angelis S, et al. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol 2009; 35(4):867-72.
41. Kang HJ, Lee SH, Price JE, Kim LS. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice. model. Breast J 2009; 15(3):223-9.
42. Labbozzetta M, Notarbartolo M, Poma P, Maurici A, Inguglia L, Marchetti P, et al. Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer. Ann N Y Acad Sci 2009; 1155:278-83.
43. Liu Q, Loo WT, Sze SC, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription. Phytomedicine 2009; 16(10):916-22.
44. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem Biol Interact 2009; 181(2):263-71.
45. Grynkiewicz G, Slifirski P. Curcumin and curcuminoids in quest for medicinal status. Acta biochimica Polonica 2012; 59(2): 201-12.
46. Berthelet E, Truong PT, Musso K, Grant V, Kwan W, Moravan V, et al. Preliminary reliability and validity testing of a new Skin Toxicity Assessment Tool (STAT) in breast cancer patients undergoing radiotherapy. Am J Clin Oncol 2004; 27(6):626-31. (Pubitemid 39603279)
47. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10(20): 6847-54. (Pubitemid 39383033)
48. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer research 2001; 21(4B):2895-900.
49. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6:10.
50. Mimeault M, Batra SK. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chinese Medicine 2011; 6:31.
51. Sarkar FH, Li Y, Wang Z, Padhye S. Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Current pharmaceutical design 2010; 16(16):1801-12.
52. Tamvakopoulos C, Dimas K, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, et al. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res 2007; 13(4):1269-77. (Pubitemid 46424068)
53. Tham CL, Liew CY, Lam KW, Mohamad AS, Kim MK, Cheah YK, et al. A synthetic curcuminoid derivative inhibits nitric oxide and proinflammatory cytokine synthesis. European J Pharmacol 2010; 628(1-3):247-54.